While we recognize the optimized sensitivity of extraprostatic prostate cancer foci detection with PSMA PET imaging resulting in a stage migration in the initial diagnosis and staging of oligometastatic prostate cancer, we also know that the management of these patients is as uncertain as ever before. This evidence concerns the gene FOLH1 and prostate cancer.